We have located links that may give you full text access.
Journal Article
Review
Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis.
Archives of Medical Science : AMS 2016 October 2
INTRODUCTION: Cyclooxygenase-2 (COX-2) is believed to be an important enzyme in the carcinogenesis of hepatocellular carcinoma (HCC). However, it is still controversial whether COX-2 expression can be regarded as a prognostic factor for HCC patients. We performed a systematic review and meta-analysis of studies assessing the clinical and prognostic significance of COX-2 expression in HCC.
MATERIAL AND METHODS: Identification and review of publications assessing clinical or prognostic significance of COX-2 expression in HCC until November 1, 2014. A meta-analysis was performed to clarify the association between COX-2 expression and clinical outcomes.
RESULTS: A total of 11 publications met the criteria and included 943 cases. Analysis of these data showed that COX-2 expression was not significantly correlated with capsular formation (OR = 0.84, 95% confidence interval (CI): 0.46-1.55, p = 0.58), tumor TNM stage (OR = 0.73, 95% CI: 0.23-2.33, p = 0.59), vascular invasion (OR = 1.04, 95% CI: 0.25-4.35, p = 0.96), tumor size (OR = 0.78, 95% CI: 0.21-2.86, p = 0.71), or tumor differentiation degree (OR = 1.08, 95% CI: 0.42-2.79, p = 0.87). However, in the identified studies, COX-2 expression was strongly associated with high alpha-fetoprotein level (OR = 1.83, 95% CI: 1.01-3.33, p = 0.05), HBsAg status (OR = 1.85, 95% CI: 1.13-3.03, p = 0.01), decreased overall survival (relative risk (RR): 1.54, 95% CI: 1.18-2.02, p = 0.001) and decreased disease-free survival (RR = 1.49, 95% CI: 1.22-1.81, p < 0.001).
CONCLUSIONS: This meta-analysis shows that COX-2 expression in HCC is associated with decreased overall and disease-free survival and thus marks a worse prognosis. Nevertheless, more large sample and well-designed studies are warranted to confirm this finding.
MATERIAL AND METHODS: Identification and review of publications assessing clinical or prognostic significance of COX-2 expression in HCC until November 1, 2014. A meta-analysis was performed to clarify the association between COX-2 expression and clinical outcomes.
RESULTS: A total of 11 publications met the criteria and included 943 cases. Analysis of these data showed that COX-2 expression was not significantly correlated with capsular formation (OR = 0.84, 95% confidence interval (CI): 0.46-1.55, p = 0.58), tumor TNM stage (OR = 0.73, 95% CI: 0.23-2.33, p = 0.59), vascular invasion (OR = 1.04, 95% CI: 0.25-4.35, p = 0.96), tumor size (OR = 0.78, 95% CI: 0.21-2.86, p = 0.71), or tumor differentiation degree (OR = 1.08, 95% CI: 0.42-2.79, p = 0.87). However, in the identified studies, COX-2 expression was strongly associated with high alpha-fetoprotein level (OR = 1.83, 95% CI: 1.01-3.33, p = 0.05), HBsAg status (OR = 1.85, 95% CI: 1.13-3.03, p = 0.01), decreased overall survival (relative risk (RR): 1.54, 95% CI: 1.18-2.02, p = 0.001) and decreased disease-free survival (RR = 1.49, 95% CI: 1.22-1.81, p < 0.001).
CONCLUSIONS: This meta-analysis shows that COX-2 expression in HCC is associated with decreased overall and disease-free survival and thus marks a worse prognosis. Nevertheless, more large sample and well-designed studies are warranted to confirm this finding.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app